At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 150 enrolled
Drug / intervention
N-acetyl glucosamine (NAG) +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
N-Acetyl Glucosamine as Therapeutic Intervention for Coronavirus Disease-19 (COVID-19)
In Brief
A Phase 1 clinical trial evaluating N-acetyl glucosamine (NAG) and Control for Coronavirus and Covid19. Completed, enrolled 150 participants across 1 site.
Detailed Summary
This study examines the efficacy of N-acetylglucosamine (NAG) in treating patients with novel coronavirus (COVID-19) infection.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronavirus, Covid19
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
202120222023202420252026
Enrollment StartNov 2020
First PostedJan 2021
Primary CompletionJan 2021
TodayJul 2026
First PostedJan 12, 2021
Enrollment StartNov 14, 2020
Primary CompletionJan 15, 2021
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 5.5 years ago
Interventions
N-acetyl glucosamine (NAG)dietary
Patients with novel coronavirus (COVID-19) will be treated with N-acetylglucosamine (NAG) (700 mg every 12 hours) as first-line treatment for 30 days, along with standard of care.
Controlother
Patients do not receive treatment with N-Acetylglucosamine. They may receive other treatments at the discretion of the treating physician, as with the treatment group.